Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aveni Foundation
Children's Oncology Group
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Var2 Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
GlaxoSmithKline
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
Valo Therapeutics Oy
NextPoint Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BioEclipse Therapeutics
Cellestia Biotech AG
Peking Union Medical College Hospital
Children's National Research Institute
Children's Hospital Los Angeles
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Emory University
Children's Oncology Group
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Children's Oncology Group
Masonic Cancer Center, University of Minnesota
Assaf-Harofeh Medical Center
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Valerio Therapeutics
Valerio Therapeutics